Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Receivables (2016 - 2025)

Historic Receivables for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $8.5 million.

  • Niagen Bioscience's Receivables rose 1987.03% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 1987.03%. This contributed to the annual value of $7.8 million for FY2024, which is 4841.42% up from last year.
  • Niagen Bioscience's Receivables amounted to $8.5 million in Q3 2025, which was up 1987.03% from $9.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Receivables ranged from a high of $12.7 million in Q1 2023 and a low of $5.2 million during Q4 2023
  • For the 5-year period, Niagen Bioscience's Receivables averaged around $7.8 million, with its median value being $7.5 million (2021).
  • Its Receivables has fluctuated over the past 5 years, first surged by 10383.97% in 2021, then tumbled by 5480.92% in 2023.
  • Over the past 5 years, Niagen Bioscience's Receivables (Quarter) stood at $7.3 million in 2021, then skyrocketed by 58.09% to $11.6 million in 2022, then crashed by 54.81% to $5.2 million in 2023, then soared by 48.41% to $7.8 million in 2024, then increased by 9.5% to $8.5 million in 2025.
  • Its Receivables was $8.5 million in Q3 2025, compared to $9.7 million in Q2 2025 and $7.1 million in Q1 2025.